[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364991-105":59,"doc-detail-364991-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","fgfr-as-a-predictive-marker-for-targeted-therapy-in-gastrointestinal-malignancies-a-systematic-review","FGFR as a Predictive Marker for Targeted Therapy in Gastrointestinal Malignancies - A Systematic Review","","The systematic review evaluates whether fibroblast growth factor receptor (FGFR) alterations can predict benefit from targeted therapy across gastrointestinal (GI) cancers. FGFR family dysregulation is discussed in relation to GI carcinomas and the clinical relevance of FGFR inhibitors, including approvals for cholangiocarcinoma, contrasted with remaining uncertainties for other GI malignancies. Searches in major databases identified 18 studies using FGFR-focused terms. Evidence supports FGFR-targeted therapy in cholangiocarcinoma, gastro-oesophageal cancer, and hepatocellular cancer, while evidence is limited for pancreatic and colorectal cancer. The review highlights links between specific alteration types and cancer subgroups and stresses the importance of consistent molecular diagnostics in trials for reliable patient stratification.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/fgfr-as-a-predictive-marker-for-targeted-therapy-in-gastrointestinal-malignancies-a-systematic-review/364991/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/fgfr-as-a-predictive-marker-for-targeted-therapy-in-gastrointestinal-malignancies-a-systematic-review/364991.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What was the purpose of this systematic review?","Question",{"text":113,"@type":114},"To assess whether FGFR alterations have predictive value for targeted therapy across gastrointestinal malignancies and clarify where evidence is strong versus limited.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which databases and study count were included?",{"text":118,"@type":114},"The review searched CINAHL, Embase, Medline, Cochrane Library, PubMed, and Web of Science and included 18 studies.",{"name":120,"@type":111,"acceptedAnswer":121},"For which GI cancers does the review report stronger evidence for FGFR-targeted inhibitors?",{"text":122,"@type":114},"Strong evidence supports FGFR inhibitors in cholangiocarcinoma, gastro-oesophageal cancer, and hepatocellular cancer.",{"name":124,"@type":111,"acceptedAnswer":125},"Why does the review emphasize consistent molecular diagnostics?",{"text":126,"@type":114},"Because trial outcomes may not be attributable to FGFR blockade when multi-kinase inhibitors are used without prior genomic testing, and consistent diagnostics are needed to identify the most responsive patient populations.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},364991,1790206129,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":150,"preview_page_count":19,"preview_urls":151},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Journal of Gastrointestinal Cancer (2025) 56:96 [https://doi.org/10.1007/s12029-025-01214-y](https://doi.org/10.1007/s12029-025-01214-y)  \nFGFR as a Predictive Marker for Targeted Therapy in Gastrointestinal Malignancies: A Systematic Review  \nNika Seraji1 · Irina Berger2  \nAccepted: 25 March 2025 © The Author(s) 2025  \nAbstract  \nBackground Gastrointestinal (GI) cancers constitute approximately 25% of cancers worldwide. The fibroblast growth factor receptor (FGFR) family is a promising target for immunotherapy aiming to enhance survival rates. FGFR alterations are associated with GI carcinomas. Their predictive value in different malignancies remains a focus area. While FGFR inhibitors have been approved for cholangiocarcinoma (CC) therapy, uncertainties remain regarding other GI cancers.  \nMethods A systematic review was conducted using the following databases: CINAHL, Embase, Medline, Cochrane Library, PubMed, and Web of Science. The search terms included “FGFR” and each of the GI malignancies. A total of 18 studies were included in this review.  \nResults The efficacy of FGFR-targeted therapy is evident. Strong evidence supports the use of FGFR inhibitors in CC, gastro-oesophageal cancer (GC/OC), and hepatocellular cancer, while there is limited evidence for pancreatic cancer (PC) and colorectal cancer (CRC) . Alteration forms like FGFR2 fusion or rearrangement are associated with CC, while FGFR2 amplification and FGFR2b overexpression are associated with GC/OC. The administration of multi-kinase inhibitors without prior genomic testing, makes distinct study outcomes not solely attributable to the FGFR blockade.  \nConclusion FGFRs have a predictive value for GI cancers. Certain FGFR alterations are predictable for specific GI cancers. The most established FGFR-targeted therapy is for CC. It is essential to expand the FGFR research field for PC and CRC. Consistent molecular diagnostics in clinical trials are vital to comprehend the patient population with the highest efficacy.  \n* Nika Seraji[ns12g21@soton.ac.uk](ns12g21@soton.ac.uk)  \n1 Faculty of Medicine, University of Southampton, Southampton, UK  \n2 Department of Pathology, Klinikum Kassel, Kassel, Germany  \nGraphical Abstract  \nKeywords Fibroblast growth factor receptor (FGFR) · Targeted therapy · Predictive biomarker · Malignant tumour · Gastrointestinal cancers  \nAbbreviations  \nGI  \nCC iCC  \nGC  \nOC  \nSCC  \nCRC  \nPC  \nHCC  \nFGFR  \nFGF  \nNHS  \nCDC  \nGastrointestinal Cholangiocarcinoma Intrahepatic cholangiocarcinoma Gastric cancer  \nOesophageal cancer  \nSquamous cell carcinoma Colorectal cancer  \nPancreatic cancer Hepatocellular carcinoma Fibroblast growth factor receptor  \nFibroblast growth factor National health service The centers for disease control and prevention  \nNICE  \nEGFR  \nHDI  \nFDA  \nRTK  \nCASP  \nMINORS  \nRCT  \nPRISMA  \nOS  \nPFS  \nORR  \nThe national institute for health and care excellence  \nEpidermal growth factor receptor Human development index  \nFood and drug administration Receptor tyrosine kinase  \nCritical appraisal skills programme Methodological index for non-randomised studies  \nRandomised controlled trial  \nPreferred reporting items for systematic reviews and meta-analyses  \nOverall survival  \nProgression-free survival  \nObjective response rate  \nCR  \nPR  \nNGS  \nctDNA  \npts  \nM  \nFISH RT-qPCR  \nBICR  \nBICC1  \nI  \nIRRC  \nB  \nP  \nMSK-IMPACT  \nIHC  \nPD-1  \nFGFR-M  \nFGFR-W  \nKLB  \nmRECIST  \nRECIST v.1.1  \nL  \nL + N  \nSmFOLFOX6  \nELISA  \nFGF23  \nbFGF  \nNET  \nVEGFR  \nCSF-1R  \nCNT  \nComplete response/responses Partial response/responses Next generation sequencing Circulating tumor DNA Patients  \nMedian  \nFluorescence in situ hybridisation Quantitative reverse transcription polymerase chain reaction  \nBlinded independent central review Bicaudal-C1  \nInvestigator  \nIndependent radiology review committee  \nBemarituzumab Placebo  \nMemorial sloan kettering-integrated mutation profiling of actionable cancer  \ntargets  \nImmunohistochemistry Programmed cell d","cbCaistoxiQO9H76","https://ap.wps.com/l/cbCaistoxiQO9H76","pdf",1710402,25,"English","# Abstract\n# Introduction\n## Gastrointestinal cancer burden and early detection\n## FGFR as a marker for targeted therapy","[{\"question\":\"What was the purpose of this systematic review?\",\"answer\":\"To assess whether FGFR alterations have predictive value for targeted therapy across gastrointestinal malignancies and clarify where evidence is strong versus limited.\"},{\"question\":\"Which databases and study count were included?\",\"answer\":\"The review searched CINAHL, Embase, Medline, Cochrane Library, PubMed, and Web of Science and included 18 studies.\"},{\"question\":\"For which GI cancers does the review report stronger evidence for FGFR-targeted inhibitors?\",\"answer\":\"Strong evidence supports FGFR inhibitors in cholangiocarcinoma, gastro-oesophageal cancer, and hepatocellular cancer.\"},{\"question\":\"Why does the review emphasize consistent molecular diagnostics?\",\"answer\":\"Because trial outcomes may not be attributable to FGFR blockade when multi-kinase inhibitors are used without prior genomic testing, and consistent diagnostics are needed to identify the most responsive patient populations.\"}]","FGFR as a Predictive Marker for Targeted Therapy in Gastrointestinal Malignancies - A Systematic Review | PDF",1790159643,63,[152,156,160,164],{"page_no":8,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/520462cf4776288ceb6dbbf90bd0ccd1.webp",983,1305,{"page_no":14,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1ec079ee0bec4b5f3a53aa62f69ccbad.webp",982,1304,{"page_no":81,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86cc45acf725cf25e31997145ee3b5f5.webp",981,1303,{"page_no":19,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/224c4cc4de23a15e4aa09942dd1cb3ba.webp",980,1301]